UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3971809 (State ...

Nephros, Inc (NASDAQ:NEPH) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Kirin Smith ??? President-PCG Advisory Daron Evans ??? Chief Executive Officer Andy Astor ??? Chief Financial Officer and Chief Operating Officer Conference Call Participants Howard Halpern ??? Taglich Brothers Michael Brick ??? National Securities Art Winston ??? Pilot Advisors Operator Good afternoon, and welcome to the Nephros Second Quarter 2019 Financial Results Conference Call. All participants w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or ot ...

Nephros, Inc (NASDAQ:NEPH) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Group Daron Evans - Chief Executive Officer Andy Astor - Chief Operating Officer and Chief Financial Officer Conference Call Participants Howard Halpern - Taglich Brothers Art Winston - Pilot Advisors Operator Good afternoon, and welcome to the Nephros First Quarter 2019 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Af ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

Company Overview - Nephros is a commercial-stage medical device company focused on liquid purification filters and hemodiafiltration systems for end-stage renal disease patients[5] - The company's strategy prioritizes the large, fast-growing medical device sector[9, 74] - Insider ownership accounts for 50% of the company[4] Financial Performance - The company has demonstrated 10 consecutive quarters of growth, averaging 55% year-over-year[9, 74] - Gross margins are consistently between 55% and 60%[9, 74] - 2017 revenue was $3.8 million, and 2018 revenue reached $5.7 million[4] - Cash on hand as of December 31, 2018, was $4.5 million[4] Products and Markets - The total addressable market for water ultrafiltration products is over $1 billion[20] - The company is launching a pathogen diagnostic product to complement its medical device offerings[9, 74] - Nephros ultrafilters have a pore size 40 times smaller than conventional filters[27]

Nephros, Inc. (NASDAQ:NEPH) Q4 2018 Results Conference Call March 12, 2019 10:00 AM ET Company Participants Kirin Smith - PCG Advisory Group Daron Evans - CEO Andy Astor - Chief Operational and Financial Officer Conference Call Participants Michael Motley - Private Investor Claude Wydell - Private Investor Larry Cassidy - Private Investor Operator Good afternoon and welcome to the Nephros Incorporated Fourth and Full Year 2018 Financial Results Conference Call. All participants will be in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. (Exact name of registrant specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 1 ...